[Morphologic endometrium changes with tamoxifen].
Women receiving tamoxifen as adjuvant therapy for breast cancer usually develop atrophy of the endometrium. Cystic polyps as well as endocervical and clear-cell metaplasias also frequently arise in the these atrophic endometria. The invasive endometrial carcinomas we have observed in these women have all been until now either mucinous, clear-cell or serous-papillary carcinomas, that is, different from the endometrioid type of adenocarcinomas that arise under estrogenic stimulation. Our histological studies support the assumption that tamoxifen has an antiestrogenic, gestagen-like action on the endometrium; they contradict the premise that tamoxifen therapy exerts an estrogen effect.
Dallenbach-Hellweg
G
G
Institut für Pathologie, A 2, 2, Mannheim.
Hahn
U
U
Schmidt
D
D
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001284:Atrophy; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000473:pathology; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology; D005260:Female; D006801:Humans; D008679:Metaplasia; D011230:Precancerous Conditions / Q000139:chemically induced / Q000473:pathology; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen
Morphologische Endometriumveränderungen unter Tamoxifen.